Prodia Widyahusada Tbk PT

The company maintains a strong liquidity position, with a current ratio of 6.13, indicating a significant buffer of current assets over current liabilities. Its cash and equivalents amount to 110 billion IDR, and it has a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt financing. The operating cash flow of 243.28 billion IDR supports its operational needs and capital expenditures, which were -62.48 billion IDR in the latest period.

In terms of profitability, the company's return on equity (ROE) is 3.29%, and its return on assets (ROA) is 2.93%, both of which are below the typical thresholds for high-performing healthcare firms. The net income of 76.63 billion IDR reflects a healthy margin, but the operating income of 86.85 billion IDR suggests that the company is managing its operating expenses effectively.

The company's revenue is primarily concentrated in Indonesia, with no significant international operations disclosed. The business is structured around diagnostic laboratory services, and there are no additional segments reported in the latest financial data. The company's growth trajectory is positive, with a strong operating cash flow and a low debt burden, which supports its ability to invest in future growth.

The risk assessment indicates a low level of liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is stable, and there are no signs of near-term dilution pressure. The low debt-to-equity ratio and high cash reserves further support the company's financial stability.

Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company continues to focus on its core diagnostic services, and there are no major new initiatives or strategic shifts reported in the latest disclosures.

Analysts project a 9.6% upside to a mean price target of IDR 2,817.50 from the current market price.

The company maintains a negligible debt-to-equity ratio of 0.01, significantly lower than the cohort median of 0.32.

Free cash flow improved by 42.6% year-over-year to IDR 148.6 billion in the latest fiscal period.

Cash conversion efficiency stands at 3.17, well above the cohort median of 1.36, indicating strong operational cash generation.

Revenue contracted at a 3.7% compound annual growth rate over the last four years, signaling weak top-line momentum.

Return on equity of 3.29% falls below the healthcare cohort median of 4.56%, indicating subpar capital efficiency.

Return on assets of 2.93% suggests limited ability to generate profits from total asset base relative to peers.

Revenue IDR 2.28T, +1,3% YoY; Operating income −25,1% YoY.

• ▍Revenue IDR 2.28T, +1,3% YoY
• ▍Operating income −25,1% YoY
• ▍Net income −23,5% YoY
• ▍Free cash flow +42,6% YoY
• ▍Net margin 9.1%

Revenue IDR 2.25T, +1,3% YoY; Operating income −2,6% YoY.

• ▍Revenue IDR 2.25T, +1,3% YoY
• ▍Operating income −2,6% YoY
• ▍Net income +4,0% YoY
• ▍Free cash flow +407,2% YoY
• ▍Net margin 12.0%

Revenue IDR 2.22T, +1,9% YoY; Operating income −31,0% YoY.

• ▍Revenue IDR 2.22T, +1,9% YoY
• ▍Operating income −31,0% YoY
• ▍Net income −30,1% YoY
• ▍Free cash flow +62,2% YoY
• ▍Net margin 11.7%

Revenue IDR 2.18T, −17,7% YoY; Operating income −41,1% YoY.

• ▍Revenue IDR 2.18T, −17,7% YoY
• ▍Operating income −41,1% YoY
• ▍Net income −40,4% YoY
• ▍Free cash flow −118,8% YoY
• ▍Net margin 17.0%

Revenue IDR 2.65T; Operating income IDR 758.68B.

• ▍Revenue IDR 2.65T
• ▍Operating income IDR 758.68B
• ▍Net margin 23.5%